Detail of "142583-61-7"

Reference

Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial

All Rights Reserved. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Cubeddu, Luigi X.; Cubeddu, Roberto J.; Heimowitz, Todd; Restrepo, Beatriz; Lamas, Gervasio A.; Weinberg, Gloria B. (Division of Cardiology and Department of Internal Medicine, Mount Sinai Medical Center, Miami Beach, FL, USA). American Heart Journal, 152(5), e982/1-e982/5 (English) 2006 Elsevier. CODEN: AHJOA2. ISSN: 0002-8703. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) Background: Policosanol, commonly derived from purified sugar cane wax, has been reported to exert lipid-lowering effects. Policosanol is available in the United States as a nutritional supplement despite no US research clin. experience. This trial was designed to rigorously establish the lipid-lowering efficacy of policosanol as monotherapy and its potential additive and possibly synergistic effects when added to statin therapy. Methods: A randomized, parallel, double-blind, double-dummy, placebo-controlled design was used. Patients with low-d. lipoprotein cholesterol (LDL-C) levels from 140 to 189 mg/dL were assigned into 1 of 4 groups to receive policosanol 20 mg, atorvastatin 10 mg, combination therapy, or placebo for 12 wk. Results: A total of 99 patients were examd. Baseline characteristics were similar among all treatment groups. Policosanol (20 mg/d for 12 wk) did not significantly change plasma total cholesterol, LDL-C, high-d. lipoprotein cholesterol, or triglyceride levels when compared with baseline values or with values of placebo-treated patients. Atorvastatin (10 mg/d for 12 wk) reduced total cholesterol by 27% and LDL-C by 35%. Addn. of policosanol to atorvastatin failed to produce any further redn. in lipid levels above that of atorvastatin alone. Policosanol was safe and did not affect liver enzyme or creatinine phosphokinase levels. Conclusions: Policosanol did not reduce LDL-C or total cholesterol levels either alone or in combination with atorvastatin. This observation supports the need for systematic evaluation of available products contg. policosanol to det. their clin. lipid-lowering efficacy under rigorous exptl. conditions. We propose that policosanol should be added to the list of nutritional supplements lacking scientific validity to support their use.Except for chemicals metioned above, 134523-03-8 and 9000-97-9 are also used. .

Policosanol compositions, extraction from novel sources, and uses as antihypocholesteremic

Policosanol compositions, extraction from novel sources, and uses as antihypocholesteremic. Empie, Mark W.; Hilaly, Ahmad; Lane, Dennis Branin; Sanborn, Alexandra J. (Archer-Daniels-Midland Company, USA). PCT Int. Appl. WO 2003101923 A2 11 Dec 2003, 37 pp. DESIGNATED STATES: W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW; RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR. (English). (World Intellectual Property Organization). CODEN: PIXXD2.There are some reagents with their cas registry numbers 108-88-3 and 67-66-3 are used in this study. CLASS: ICM: C07C031-125. ICS: A61K031-045. APPLICATION: WO 2003-US16969 30 May 2003. PRIORITY: US 2002-PV384100 31 May 2002. DOCUMENT TYPE: Patent CA Section: 17 (Food and Feed Chemistry) Section cross-reference(s): 1, 23, 48, 63 Seed- and vegetable-processing byproduct and/or waste streams are described as contg. policosanols (i.e., C20-30 linear fatty alcs.) with various relative amts. of the various long chain fatty/waxy alcs. which are isolate by solid-liq. extn. using a solvent (e.g., ethanol) followed by policosanol recrystn. The policosanols are isolated and may be combined with other phytochem./processing products, and are used in numerous food, beverage, health and/or nutraceutical applications as antihypercholesteremics. .